Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Margherita Parolini"'
Autor:
Emilio Iannitto, Simone Ferrero, Côme Bommier, Daniela Drandi, Martina Ferrante, Krimo Bouabdallah, Sylvain Carras, Guido Gini, Vincent Camus, Salvatrice Mancuso, Luigi Marcheselli, Angela Ferrari, Michele Merli, Benoit Tessoulin, Caterina Stelitano, Kheira Beldjord, Giovanni Roti, Fabrice Jardin, Barbara Castagnari, Francesca Palombi, Lucile Baseggio, Alexandra Traverse-Glehen, Claudio Tripodo, Anna Marina Liberati, Margherita Parolini, Sara Usai, Caterina Patti, Massimo Federico, Maurizio Musso, Marco Ladetto, Emanuele Zucca, Catherine Thieblemont
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
Not available.
Externí odkaz:
https://doaj.org/article/5f4a0e9b701e495c958e1cf920f2724a
Autor:
Joaquim Reis, Luzia Travado, Alexander Scherrer, Thanos Kosmidis, Stefanos Venios, Paris Emmanouil Laras, Gabrielle Oestreicher, Markus Moehler, Margherita Parolini, Alessandro Passardi, Elena Meggiolaro, Giovanni Martinelli, Elisabetta Petracci, Chiara Zingaretti, Sotiris Diamantopoulos, Maria Plakia, Charalampos Vassiliou, Suheib Mousa, Robert Zifrid, Francesco Giulio Sullo, Chiara Gallio
Publikováno v:
JMIR Research Protocols, Vol 12, p e45475 (2023)
BackgroundAccording to Europe’s Beating Cancer Plan, the number of cancer survivors is growing every year and is now estimated at over 12 million in Europe. A main objective of the European Commission is to ensure that cancer survivors can enjoy a
Externí odkaz:
https://doaj.org/article/e563194a52194f358562e88a8981aa68
Autor:
Renato Bassan, Arianna Masciulli, Tamara Intermesoli, Ernesta Audisio, Giuseppe Rossi, Enrico Maria Pogliani, Vincenzo Cassibba, Daniele Mattei, Claudio Romani, Agostino Cortelezzi, Consuelo Corti, Anna Maria Scattolin, Orietta Spinelli, Manuela Tosi, Margherita Parolini, Filippo Marmont, Erika Borlenghi, Monica Fumagalli, Sergio Cortelazzo, Andrea Gallamini, Rosa Maria Marfisi, Elena Oldani, Alessandro Rambaldi
Publikováno v:
Haematologica, Vol 100, Iss 6 (2015)
Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic leukemia, to avoid the long-term toxicity associated with cranial irradiation. In a randomized, phase II trial enrolling 145 adult patient
Externí odkaz:
https://doaj.org/article/5cc9ce3243834d5d8ea2c0feb55dd0c8
Autor:
Orietta Spinelli, Manuela Tosi, Barbara Peruta, Marie Lorena Guinea Montalvo, Elena Maino, Anna Maria Scattolin, Margherita Parolini, Piera Viero, Alessandro Rambaldi, Renato Bassan
Publikováno v:
Mediterranean Journal of Hematology and Infectious Diseases, Vol 6, Iss 1, Pp e2014062-e2014062 (2014)
Acute lymphoblastic leukemia (ALL) is curable in about 40-50% of adult patients, however this is subject to ample variations owing to several host- and disease-related prognostic characteristics. Currently, the study of minimal residual disease (MRD)
Externí odkaz:
https://doaj.org/article/bc42b579facf44e2a47e43a0f0dd527a
Autor:
Tamara Intermesoli, Alessandro Rambaldi, Giuseppe Rossi, Federica Delaini, Claudio Romani, Enrico Maria Pogliani, Chiara Pagani, Emanuele Angelucci, Elisabetta Terruzzi, Alessandro Levis, Vincenzo Cassibba, Daniele Mattei, Giacomo Gianfaldoni, Anna Maria Scattolin, Eros Di Bona, Elena Oldani, Margherita Parolini, Nicola Gökbuget, Renato Bassan
Publikováno v:
Haematologica, Vol 98, Iss 11 (2013)
We evaluate the long-term results of a prospective clinical study enrolling more than 100 adult patients with Burkitt lymphoma/leukemia. Depending on extent of disease, treatment consisted of six to eight rituximab infusions and four to six courses o
Externí odkaz:
https://doaj.org/article/bf3bfa18f9264bb7b13fe32de4aaa3d1
Autor:
Joaquim Reis, Luzia Travado, Alexander Scherrer, Thanos Kosmidis, Stefanos Venios, Paris Emmanouil Laras, Gabrielle Oestreicher, Markus Moehler, Margherita Parolini, Alessandro Passardi, Elena Meggiolaro, Giovanni Martinelli, Elisabetta Petracci, Chiara Zingaretti, Sotiris Diamantopoulos, Maria Plakia, Charalampos Vassiliou, Suheib Mousa, Robert Zifrid, Francesco Giulio Sullo, Chiara Gallio
BACKGROUND According to Europe’s Beating Cancer Plan, the number of cancer survivors is growing every year and is now estimated at over 12 million in Europe. A main objective of the European Commission is to ensure that cancer survivors can enjoy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1114d838cb1dcea1579fde4b38942ffd
https://doi.org/10.2196/preprints.45475
https://doi.org/10.2196/preprints.45475
Autor:
Agostino Cortelezzi, Fabio Ciceri, Anna De Grassi, Ernesta Audisio, Emanuele Angelucci, Margherita Parolini, Roberto Raimondi, Federico Lussana, Alessandro Rambaldi, Irene Cavattoni, Claudio Romani, Elisabetta Terruzzi, Arianna Masciulli, Orietta Spinelli, Manuela Tosi, Anna Maria Scattolin, Tamara Intermesoli, Francesca Gianni, Daniele Mattei, Elena Oldani, Renato Bassan, Chiara Cattaneo, Francesco Mannelli, Cristina Boschini, Erika Borlenghi
Publikováno v:
Biology of Blood and Marrow Transplantation. 22:1983-1987
Allogeneic stem cell transplantation (alloHSCT) in first complete remission (CR1) remains the consolidation therapy of choice in Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL). The prognostic value of measurable levels of minimal resi
Autor:
Alessandro Isidori, Darina Ocadlikova, Sarah Parisi, Mariangela Lecciso, Giulia Corradi, Giuseppe Visani, Michele Cavo, Margherita Parolini, Dorian Forte, Federica Loscocco, Valentina Salvestrini, Marilena Ciciarello, Antonio Curti
Publikováno v:
Cancer Research Frontiers. 2:226-251
Autor:
Ernesta Audisio, Enrico Pogliani, Daniele Mattei, Vincenzo Cassibba, Elena Oldani, Claudio Romani, Monica Fumagalli, Alessandro Rambaldi, Filippo Marmont, Sergio Cortelazzo, Agostino Cortelezzi, Anna Maria Scattolin, Arianna Masciulli, Erika Borlenghi, Consuelo Corti, Manuela Tosi, Renato Bassan, Rosa Maria Marfisi, Andrea Gallamini, Giuseppe Rossi, Orietta Spinelli, Margherita Parolini, Tamara Intermesoli
Publikováno v:
Haematologica. 100:786-793
Developing optimal radiation-free central nervous system prophylaxis is a desirable goal in acute lymphoblastic leukemia, to avoid the long-term toxicity associated with cranial irradiation. In a randomized, phase II trial enrolling 145 adult patient
Autor:
Orietta Spinelli, Piera Viero, Renato Bassan, Marie Lorena Guinea Montalvo, Elena Maino, Manuela Tosi, Barbara Peruta, Margherita Parolini, Anna Maria Scattolin, Alessandro Rambaldi
Publikováno v:
International Journal of Hematologic Oncology. 3:419-431
SUMMARY While adult acute lymphoblastic leukemia (ALL) is curable in 40–50% of the patients, the individual prognosis is rather unpredictable due to associated biological and clinical risk factors. In both B- and T-precursor ALL, minimal residual d